Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10947963 | 0.83 | TDP1 (0.42) | APLNRAKT1TDP1CA1CA2 | |
| SCHEMBL240769 | 0.80 | CA1 (0.42) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL247123 | 0.78 | TDP1 (0.44) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL13625265 | 0.78 | APLNR (0.44) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL22018439 | 0.78 | TDP1 (0.44) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL20578018 | 0.78 | MEN1 (0.42) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL101218 | 0.78 | DGAT1 (0.46) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL4648803 | 0.78 | TDP1 (0.53) | TDP1CA1CA2MEN1KMT2A | |
| SCHEMBL1926406 | 0.77 | CA2 (0.40) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL20288786 | 0.77 | CA1 (0.43) | APLNRTDP1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | claimed |
| WO-2009137739-A1 | PROCESSES FOR THE PREPARATION OF O-[5-[4-AMINO-THIAZOL-2-YL]-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | claimed |
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2009137739-A1 | PROCESSES FOR THE PREPARATION OF O-[5-[4-AMINO-THIAZOL-2-YL]-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | THOP1, HPD, TH | APLNR 3645/4885AKT1 3469/4885TDP1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.